Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > News > Anti-Cancer Candidate Shown to Be Well Tolerated

October 20th, 2006

Anti-Cancer Candidate Shown to Be Well Tolerated

Abstract:
Calando Pharmaceuticals, a leading siRNA therapeutics company and a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced results of a pilot safety-study using Calando’s lead siRNA therapeutic candidate in non-human primates.

Source:
businesswire

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Chemists strike nano-gold: 4 new atomic structures for gold nanoparticle clusters: Research builds upon work by Nobel Prize-winning team from Stanford University April 28th, 2015

Self-assembling biomaterial forms nanostructure templates for human tissue formation April 27th, 2015

International research team discovers new mechanism behind malaria progression: Findings provide a new avenue for research in malaria treatment April 27th, 2015

Scientists join forces to reveal the mass and shape of single molecules April 27th, 2015

Announcements

Chemists strike nano-gold: 4 new atomic structures for gold nanoparticle clusters: Research builds upon work by Nobel Prize-winning team from Stanford University April 28th, 2015

The 16th Trends in Nanotechnology International Conference (TNT 2015) unveils 25 Keynote Speakers: Call for abstracts open April 27th, 2015

Graphenea celebrates fifth anniversary April 27th, 2015

Sensor Designed in Iran Able to Remove Formaldehyde Gas from Environment April 27th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project